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ABSTRACT: It is commonly observed that hydrophobic molecules alone cannot self-
assemble into stable nanoparticles, requiring amphiphilic or ionic materials to support
nanoparticle stability and function in vivo. We report herein newly self-assembled
nanomedicines through entirely different mechanisms. We present proof-of-concept
methodology and results in support of our hypothesis that disulfide-induced nanomedicines
(DSINMs) are promoted and stabilized by the insertion of a single disulfide bond into
hydrophobic molecules, in order to balance the competition between intermolecular forces
involved in the self-assembly of nanomedicines. This hypothesis has been explored through
diverse synthetic compounds, which include four first-line chemotherapy drugs (paclitaxel,
doxorubicin, fluorouracil, and gemcitabine), two small-molecule natural products and their
derivatives, as well as a fluorescent probe. Such an unprecedented and highly reproducible
system has the potential to serve as a synthetic platform for a wide array of safe and effective
therapeutic and diagnostic nanomedicine strategies.
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The field of nanomedicine is developing worldwide and isexpected to bring radical solutions to many of modern
medicine’s limitations in drug delivery. The main challenges in
nanomedicine involve efforts to improve cargo loading
efficiency, pharmacokinetics (PK), therapeutic efficacy, live
imaging, and ultimately clinical translation. Self-assembly of
nanomaterials provides an attractive means by which to
precisely engineer nanomedicines with distinct biophysico-
chemical properties, thus simplifying the optimization of
formulation.1,2 At the molecular level, self-assembly involves
competition between intermolecular (or thermodynamic)
forces.3 The forces are mainly van der Waals attraction and
electrostatic repulsion, the former motivating agglomeration in
order to minimize the free energy of the system, and the latter
stabilizing nanoparticles (NPs) by repulsion of surrounding
NPs. When these forces balance, agglomeration stops such that
NPs are successfully self-assembled.3 Force balancing relies
solely on either amphiphilic structures or ionic interactions with
drugs. Hydrophobic drugs can self-assemble into NPs by either
formation of micelles with amphiphilic surfactant molecules or
by structure modification as amphiphilic prodrugs (e.g.,
conjugates to PEG, dendrimers, polypeptides, hydrogels).4−10
Ionic drugs, on the other hand, can be coupled on the surface of
oppositely charged colloidal particles, ultimately resulting in
multilayered polyelectrolyte self-assembly.11−13 However, as
such systems present a variety of challenges in development,
including formulation stability as well as drug loading and
release, the generation of new nanomaterials with self-balancing
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intermolecular force properties may be able to overcome the
limitations of more conventional methods.
We report herein new nanomaterials composed of hydro-
phobic prodrugs that self-assemble into NPs by means
independent of traditional amphiphilic or ionic interactions.
Self-balancing intermolecular forces have been established by
simple insertion of a disulfide bond between (1) two
hydrophobic drugs, paclitaxel (PTX) or doxorubicin (DOX),
and vitamin E (VE), (2) hydrophilic drugs fluorouracil (5-FU)
or gemcitabine (GEM) and hydrophobic stearic acid (SA), and
(3) a water-soluble fluorescent probe, sulforhodamine B (SRB),
and VE. The synthesized molecules self-assemble into stable
disulfide-induced nanomedicines (DSINMs) in aqueous
suspension. In addition, we have synthesized two natural
anticancer molecules and their derivatives, each of which
contains a disulfide bond, and examined how their structures
affect self-assembly.
We also present proof-of-concept methodology and results in
support of our hypothesis that DSINMs are promoted and
stabilized by the insertion of a disulfide bond to balance
intermolecular forces. The structures and dynamic properties of
the DSINMs at the molecular level have been explored, as have
the mechanisms by which S−S bonds support the self-assembly
and stabilization of the DSINMs. The PK, anticancer activity
and tumor imaging of the DSINMs in vitro and in vivo have
also been characterized, highlighting the strong potential of our
synthetic platform in diverse nanomedical applications.
It is commonly understood that hydrophobic molecules
alone cannot self-assemble into NPs. PTX and VE represent
common molecules that, upon aqueous exposure, form large
crystals or droplets (Figure 1a and b). When PTX is conjugated
with VE as a prodrug (PTX−VE, Supporting Information
Scheme S1), the hydrophobicity of the product is further
increased, resulting in considerable aggregation during self-
assembly (Figure 1c). Our data, however, shows that a single
Figure 1. Characterization of various hydrophobic drugs dispersed in water. (a−c) Molecular structures of PTX, VE and PTX−VE and TEM images
after dispersion in water. The sample in (b) (VE) was stained on the TEM grid immediately after the self-assembling process. Molecular structure of
PTX−S−S−VE and TEM (d) and SEM (d) image of PTX−S−S−VE DSINMs. (f) Particle size distribution of PTX−S−S−VE DSINMs in DI water
stored at 4 °C for two months. Scale bar: (a−b), 1 μm; (c−d), 0.2 μm; (e), 100 nm.
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disulfide-bond inserted between the compounds (Figure 1d and
e and Supporting Information Scheme S2 for synthesis) does
not alter the hydrophobicity of the prodrug (Supporting
Information Figure S1) but transforms its properties in aqueous
suspension such that the self-assembled DSINMs are formed by
prodrug alone (Figure 1e). The mean diameter of PTX−S−S−
VE DSINMs was found to be 113 ± 5 nm (n = 3) with a
unimodal size distribution (PDI < 0.16) as measured by quasi-
elastic light scattering (Supporting Information Figure S2). The
DSINMs exhibited excellent storage stability, with no
significant change in the size over two months at 4 °C (Figure
1f). Such colloidal stability could be inferred by the particles’
negative ζ potential (ζ potential = −29.2 mV). From the
respective contributions of the molecular weights of PTX and
VE in the conjugate, it was possible to calculate that the parent
drug (PTX) loading was as high as 60 wt %, considerably
Figure 2. Illustration of the role of disulfide bond in self-assembly of DSINMs. (a) TEM image of PTX−S−S−VE DSINMs after incubation in 2.5
mM GSH for 0.5 h. (b) Molecular structure of PTX−S−VE and TEM image of PTX−S−VE after dispersion in water. (c−d) Molecular structures of
DOX−S−S−VE and DOX−S−S−SA and TEM images of DOX−S−S−VE and DOX−S−S−SA DSINMs. Scale bar: (a−c), 0.2 μm; (d), 0.5 μm.
Figure 3. Molecular structures and TEM images of natural histone deacetylase inhibitors (HDACIs) and their derivatives after dispersion in water.
(a) PSF, (b) PSF−D, (c) PSA, (d) PSA−D. Scale bar: (a−b), 0.2 μm; (c), 1 μm; (d), 0.2 μm.
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higher than that of current commercially available dosage forms
of PTX such as Taxol (1%) and Abraxane (10%).
Our initial expectation in exploring further the DSINM
formulation was that the disulfide bond represents a key
structure for self-assembly and stability. Indeed, successful
glutathione (GSH) mediated reduction of the disulfide linkages
in PTX−S−S−VE DSINMs caused the DSINMs to precipitate
(Figure 2a), indicating that the architectural structures of the
DSINMs are stabilized by the intact S−S. Agglomeration had
also been observed (Figure 2b) in our attempts to formulate
thioether-conjugated prodrugs into nanoparticles (PTX−S−
VE, Supporting Information Scheme S3). In addition to the S−
S moiety, we considered that VE or PTX may also be inherently
responsible for the DSINM formation. Both the prodrug
DOX−S−S−VE (Supporting Information Scheme S4) and the
prodrug DOX−S−S−SA (Supporting Information Scheme S5)
were able to self-assemble into DSINMs with unimodal size
distribution (Figure 2c and d and Supporting Information
Figure S2). Disulfide bonds are fairly stable in normal biological
conditions but are rapidly cleaved through thiol−disulfide
exchange reactions facilitated by intracellular reducing mole-
cules, especially GSH. It has been demonstrated that GSH
concentrations in tumor cells (2−8 mM) are much higher than
in blood plasma (1−2 μM).13,14 Our data showed that the
cleavage of S−S in PTX−S−S−VE by GSH results in the
formation of PTX-SH, a less sterically hindered and more polar
molecule. The hydrolysis rate of PTX−S−S−VE in the
presence of GSH is far greater than that of PTX−VE (76%
of PTX was released from PTX−S−S−VE vs <1% from PTX−
VE after 24 h in PBS containing 1.0 mM GSH) (data not
Figure 4. Characterization of the structure and formation of DSINMs. (a) MD simulations of tetrameric PTX−S−S−VE in water. The carbons are
colored according to their molecule of origin: blue (VE), orange (PTX), and yellow (S−S). (b) Imaging the dynamics of crystal growth. Ethanol
containing PTX−VE and PTX−S−S−VE was placed onto a glass slide. After drying and desiccating, a drop of water was added to each sample, the
slides were placed into a humidified chamber at room temperature for various hydration times and pictures were taken. The left panel (I, III, and V)
shows PTX−VE and the right panel (II, IV, and VI) PTX−S−S−VE. (c) The electrostatic potential map of PTX−S−S−VE.
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shown). This indicates another advantage that DSINMs may
offer for the enhanced delivery of anticancer drugs. Addition-
ally, DSINMs are capable of delivering combined drugs
(Supporting Information Figures S3 and S4).
Disulfide bonds are found in many small molecule natural
products,14,15 such as psammaplin F (PSF) and psammaplin A
(PSA) isolated from the sponge Pseudoceratina purpurea. PSF
and PSA exert anticancer activity through inhibition of both
histone deacetylase (HDAC) and DNA methyltransferase.16
We synthesized these two natural molecules and their
derivatives (Figure 3 and Supporting Information Schemes S6
to S8) to evaluate whether they would self-assemble into
DSINMs. The synthesized compounds showed similar
anticancer cell and HDAC activities (Supporting Information
Table S1). As shown in Figure 3a, PSF failed to form DSINMs,
possibly because of its strongly polar carboxyl group. This was
verified by synthesizing a derivative called PSF−D, in which the
carboxyl group was replaced by a weakly polar group, t-
butyloxycarbonyl. This derivative compound successfully self-
assembled into DSINMs (Figure 3b, Supporting Information
Figure S2). PSA, on the other hand, was able to self-assemble
into DSINMs (Figure 3c), but its size (>400 nm, Supporting
Information Figure S2) was bigger than that of PSF−D. The
increased size may have been due to the polarity of two
substituted phenylalanine (PHE) amides linked to both sides of
the S−S (though not as strongly as the carboxyl group for
PSF). Therefore, we synthesized a PSA derivative (PSA−D) in
which one PHE amide was substituted with a low-polar moiety
di(phenylaminocarbonyl) group, resulting in the formation of
DSINMs of 90 nm in size (Figure 3d and Supporting
Information Figure S2). All of this data suggests that the
polarity of moieties that flank S−S also play an important role
in the self-assembly of DSINMs.
To explore the self-assembling behavior of the DSINMs,
molecular dynamics (MD) simulations for the tetramer PTX−
S−S−VE were performed. The final MD simulation position
after 10 ns in water is shown in Figure 4a (right side).
Molecules were initially arranged approximately 10 Å apart (left
panel) to support an unmanipulated assembly process. Our
data indicated that four molecules quickly came together to
form a cluster of tetramers. As soon as the self-assembly was
completed, the conformation did not change much. Only
movement of the whole cluster was observed. As shown in
Figure 4a, the long alkyl chains of VE are curved inside the
cluster and there are no direct interactions between S−S bonds
(indicated by arrows). Considering the structure of the
tetramer, we can assume that the driving forces for the self-
assembly of the DSINMs are nonbonded hydrophobic
interactions, with PTX interacting with PTX, PTX with VE,
or VE with VE. However, when the S−S bonds are broken,
more energetically favorable conformations may be possible
between components, disrupting the DSINM structure.
PTX−VE, which contains no S−S linkage, fails to form NPs
through a self-assembly process, instead forming crystal
aggregates. It is known that crystal growth yields an ordered
and repeating pattern of atoms or molecules extending in all
three spatial dimensions, precipitating product from solution in
favor of solvent−solvent interactions. For self-assembly of NPs,
such a thermodynamically favored process needs to be
abrogated and assembled structures forced to interact in a
direct way with the solution phase. Structural interactions
observed in the MD simulations suggest that self-assembly of
DSINMs may be supported through a hindrance of
crystallization due to inclusion of the disulfide bond. To
explore this concept further, we examined the crystallization
kinetics of PTX−VE and PTX−S−S−VE by imaging. As shown
in Figure 4b-I and II, both PTX−VE and PTX−S−S−VE
Figure 5. Characterization of PEGylated DSINMs for their physical image, plasma concentrations, anticancer activity, toxicity and tumor imaging.
(a) TEM image of PTX−S−S−VE DSINMs PEGylated with 15% (w/w) DSPE-PEG2000. (b) Plasma concentration profiles of PEGylated and non-
PEGylated PTX−S−S−VE DSINMs compared with Taxol (n = 3). (c) Antitumor effects in mice models, ** p < 0.01 (Student’s t-test, paired, two
sided), compared with Taxol group and saline group (n = 5). (d) Kidney and liver function parameters in PEGylated PTX−S−S−VE DSINM and
saline treated control groups (n = 5). (e) Tumor imaging in live mice. The tumor (indicated by arrows) bearing mice were imaged 2 and 4 h after
injection of free SRB and PEGylated SRB−S−S−VE DSINMs. Images at 8, 12, and 48 h are shown in Supporting Information Figure S9.
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formed amorphous precipitate after ethanol evaporation. Two
hours after hydration, crystals were observed for PTX−VE
(Figure 4b-III). In contrast, no crystals were detected for PTX−
S−S−VE. Instead, the hydration induced spherical particles of
diameter <10 μm (Figure 4b-IV). At longer hydration times
(∼12 h), larger crystals were formed for PTX−VE (Figure 4b-
V), whereas small crystals were observed in the PTX−S−S−VE
sample (Figure 4b-VI). Thus, we can infer that simple insertion
of S−S in the prodrugs serves in part to inhibit crystallization
and drive the prodrugs instead toward the formation of
nanoparticles.
The ζ potential data showed the surface charge of the
DSINMs to be −20 to −30 mV, an important property
stabilizing the particles. Considering the MD analysis already
shown, one would expect the PTX portion of PTX−S−S−VE,
which contains some polar moieties (e.g., OH or CO), to
expose itself at the surface of particles in order to stabilize the
particle−solution interface. We next tested how the S−S moiety
contributes to the charge. The calculation of the charge density
in aqueous solution was based on the self-consistent reaction
field (SCRF) method with the polarizable continuum model
(PCM).17,18 It was done using the GAUSSIAN 03 program and
optimized using the PM3 method. As shown in Figure 4c, PTX
(left portion) is the major negatively charged donor. VE (right
portion) and the two sulfur atoms (central portion) do not
contribute to the negative charge. However, a negative charge
coming mainly from oxygen is concentrated near the S−S
bond. It is well known that S−S bonds show a distinct
preference for dihedral angles approaching 90°. This may play
an essential role in balancing intermolecular forces and
establishing a favorable conformation, that is, exposing the
high density of negative charge on the DSINMs surface and
contributing to the overall disruption of crystal formation.
PEGylation of NPs provides an effective means to reduce
clearance by the reticuloendothelial system (RES).19 We,
therefore, PEGylated DSINMs by mixing 15% (w/w) DSPE-
PEG2000 with PTX−S−S−VE DSINMs. TEM images clearly
confirmed PEGylation of DSINMs (Figure 5a). The particle
size of PEGylated DSINMs was 124.9 nm (Supporting
Information Figure S2, last image), and ζ potential was
−28.7 mV. To evaluate the behavior of the DSINMs in mice,
the PTX−S−S−VE DSINMs with and without PEGylation
were administered systemically. Plasma concentration of PTX−
S−S−VE was measured as a function of time postinjection. The
data was fitted to a noncompartmental pharmacokinetic model
(Figure 5b and Supporting Information Table S2). Non-
PEGylated DSINMs and Taxol were cleared rapidly from the
blood. However, the circulation time of PEGylated DSINMs
was greatly improved, yielding a terminal half-life (t1/2) of 25.74
± 7.66 h compared to a t1/2 of 1.47 ± 0.16 h (p < 0.05,
Student’s t-test, paired, two sided) for Taxol. The AUC0−t
values of PEGylated PTX−S−S−VE DSINMs were 250-fold
higher than those of Taxol (p < 0.01, Student’s t-test, paired,
two sided). Altered biodistribution profiles of PEGylated
DOX−S−S−SA DSINMs provide additional information that
PEGylation can improve the blood retention of DSINMs
(Supporting Information Figure S5). All these results suggested
that the PEGylated DSINMs may be likely to preferentially
accumulate in solid tumors to a greater extent than Taxol via
the enhanced permeability and retention (EPR) effect.
To evaluate the in vivo antitumor efficacy, human
epidermoid carcinoma cell line KB-3-1 tumor bearing mice
were IV injected with PEGylated PTX−S−S−VE DSINMs or
Taxol at PTX equivalent doses of 5 mg/kg every second day,
starting 6 days after inoculation (when tumor diameter was 4−
6 mm). Compared with Taxol, PEGylated PTX−S−S−VE
DSINMs showed significant inhibition of the KB-3-1 tumors
(Figure 5c, p < 0.01, Student’s t-test, paired, two sided). This
significantly improved in vivo efficacy could be attributed to the
enhanced PTX−S−S−VE PK profiles mentioned above that
would result in greater accumulation of drug at the tumor site.
No weight loss occurred in the mice treated with the
PEGylated PTX−S−S−VE DSINMs (Supporting Information
Figure S6), demonstrating the tolerability of the particles.
In order to determine the safety of the PTX−S−S−VE
DSINMs for IV administration, the hemolytic potential of the
formulation was evaluated (Supporting Information Figure S7).
Levels of serum aspartate transaminase (AST), alanine
transaminase (ALT), and blood urea nitrogen (BUN) were
also examined to explore hepatic and renal toxicity. After mice
(n = 5) were successively administrated PEGylated PTX−S−
S−VE DSINMs daily for 5 days at PTX equivalent doses of 10
mg/kg, the ALT, AST, and BUN levels were not significantly
different from those in the saline treated control group (Figure
5d). Taking the hemolytic test and liver and kidney function
tests together, the PTX−S−S−VE DSINMs exhibited good
safety.
The DSINMs ability to carry water-soluble drugs 5-FU and
GEM encouraged us to explore whether they could also carry a
water-soluble fluorescent probe, namely sulforhodamine B
(SRB), for tumor imaging. Both SRB−VE and SRB−S−S−VE
were synthesized (Supporting Information Scheme S9). Again,
a single S−S insertion turned what would otherwise form large
aggregates (SRB−VE) into DSINMs (Supporting Information
Figure S8, SRB−S−S−VE). Tumor imaging was performed for
free SRB and PEGylated SRB−S−S−VE DSINMs, after
injection into tumor bearing mice. Whole body imaging
showed that no fluorescence signal was detectable in the
tumors in the mice injected with free SRB throughout the
entire imaging process. However, for the PEGylated DSINMs,
the fluorescence signal was detected from the tumor at 2 h
(Figure 5e) and reached a maximum level between 4 and 8 h
after injection. It then decreased until no signal was detectable
2 days after injection (Supporting Information Figure S9).
Therefore, it is expected that PEGylated DSINMs, when
carrying fluorophores, may represent a promising theranostic
tool for tumor imaging.
DSINMs show strong potential for use as an entirely new
nanomedicine platform for self-assembly of NPs in drug
delivery and imaging. The inserted S−S bond plays a unique
role in balancing the intermolecular forces that control the self-
assembly of the NPs. Our MD simulation results support the
view that dihedral angles of 90° are generated at the disulfide
linkage during the self-assembly process, generating a stable
conformation of the prodrugs in a nonregular and nonperiodic
manner (Figure 4a). Further analysis of the crystallization
kinetics with and without the disulfide linkage suggests that S−
S bonds abrogate crystal growth during self-assembly. In
addition, the configuration of S−S bonds that are not sterically
hindered and project from the cluster (Figure 4c) may
contribute to the stabilization of the DSINMs by presenting a
high density of negative charge (near the S−S bonds) at the
surface.
PTX prodrug has been employed here as a model for the
proof-of-concept studies of our DSINMs. A prodrug is a
bioreversible derivative of an active drug, and it is commonly
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included in drug design and development. As many as 14% of
all new approved drugs worldwide can be classified as
prodrugs.20 Many efforts have been made to develop PTX
prodrugs,21,22 and nanoformulations such as Taxol and
Abraxane have been developed. Toxicity and the short t1/2 of
PTX are problems with the use of Taxol.23,24 Although
Abraxane has been shown to have several practical advantages
over Taxol, it does not significantly improve the PK or
biodistribution (BD) of the PTX.25,26 As shown in Figure 5b to
d and Supporting Information Figures S5 and S7 and Table S2,
DSINMs present markedly reduced toxicity by comparison and
show significant improvement in PK and therapeutic efficacy.
The increased number of poorly soluble compounds in drug
development has become an industry wide concern for which
the development of advanced delivery systems has predomi-
nated as a potential solution.27 DSINM technology expands
formulation development potential by utilizing novel synthetic
chemistry in the physical self-assembly process, presenting
opportunities for the development of novel nanocarriers with
improved loading and stability while remaining amenable to
modification and coformulation with traditional materials.
DSINMs have been successfully tested with four first line
chemotherapy drugs (PTX, DOX, 5-FU, and GEM), two
anticancer molecules of natural origin, and a fluorescent probe
for live animal tumor imaging. We believe that DSINMs can be
used to promote the screening of a wide library of small
molecules with promising anticancer properties for clinical
translation.
In summary, our data has shown that insertion of a single
disulfide bond can transform hydrophobic prodrugs and
imaging probe into suitable nanomaterials for molecular self-
assembly independent of excipients. Such reliable self-assembly
dramatically increases drug loading and alleviates concerns over
excipient associated adverse effects. The PEGylated DSINMs
have shown both improved PK and anticancer efficacy over
traditional PTX formulations, with suitable tumor imaging
capability. The DSINM technology, which has not been
previously demonstrated, is shown to be highly reproducible
and should motivate the development of new nanomedicines
for drug delivery and imaging.
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